$费森尤斯医疗(FMS)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2019-02-20 AccNo: 0001104659-19-009480 Size: 1 MB 网页链接
公告转发:0回复:1喜欢:0

全部评论

风箱2019-02-27 20:57

Fresenius Medical Care achieves revised 2018 targets and accelerates investments for future growth
· Growth trend unchanged: organic revenue growth of 4% for full year 2018
· Net income growth of 60% (14% on a comparable basis) at constant currency
· 22nd consecutive dividend increase proposed: +10% to EUR 1.17
· Share buyback program of up to EUR 1bn over the next 2 years
· Meaningful investments in 2019 to capture future growth opportunities and optimize cost base
· Significantly accelerated net income growth in 2020 expected.